| Literature DB >> 33187326 |
Maria Lisa Dentici1,2, Paola Bergonzini3, Francesco Scibelli3, Cristina Caciolo3, Paola De Rose3, Francesca Cumbo3, Viola Alesi4, Rossella Capolino1,2, Ginevra Zanni2,5, Lorenzo Sinibaldi1,2, Antonio Novelli4, Marco Tartaglia2, Maria Cristina Digilio1,2, Bruno Dallapiccola6, Stefano Vicari3,7, Paolo Alfieri3.
Abstract
7q11.23 Microduplication (dup7q11.23) syndrome is a rare autosomal dominant disorder due to a recurring 1.5 to 1.8 Mb duplication of the Williams-Beuren Syndrome critical region. Dup7q11.23 has been associated with several neuro-behavioral characteristics such as low cognitive and adaptive functioning, expressive language impairment, anxiety problems and autistic features. In the present study, we analyze the clinical features of ten individuals in which array-CGH detected dup7q11.23, spanning from 1.4 to 2.1 Mb. The clinical characteristics associated with dup7q11.23 are discussed with respect to its reciprocal deletion. Consistent with previous studies, we confirm that individuals with dup7q11.23 syndrome do not have a homogeneous clinical profile, although some recurring dysmorphic features were found, including macrocephaly, prominent forehead, elongated palpebral fissures, thin lip vermilion and microstomia. Minor congenital malformations include patent ductus arteriosus, cryptorchidism and pes planus. A common finding is hypotonia and joint laxity, resulting in mild motor delay. Neuropsychological and psychodiagnostic assessment confirm that mild cognitive impairment, expressive language deficits and anxiety are recurring neurobehavioral features. New insights into adaptive, psychopathological and neurodevelopmental profiles are discussed.Entities:
Keywords: Williams–Beuren Syndrome; anxiety disorder; congenital anomalies; dup7q11.23; duplication; intellectual disability
Year: 2020 PMID: 33187326 PMCID: PMC7697259 DOI: 10.3390/brainsci10110839
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Clinical features of our cohort of 10 patients affected by 7q11.23 microduplication syndrome.
| Patient N | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | P10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| M | M | F | M | F | M | F | M | M | M | 7M; 3F |
|
| 7.7 | 9.10 | 5.7 | 5.6 | 4.9 | 12.3 | 9.2 | 7.5 | 7.8 | 11.3 | M: 8; SD: 2.6 |
|
| 3 | 6 | 3 | 3 | 1.6 | 8.6 | 7.6 | 3.6 | 4 | 11 | M: 6.4; SD: 3.1 |
|
| 7q11.23(72,726,578–74,119,570)x3 | 7q11.23(72,726,578–74,139,390)x3 | 7q11.23(72,726,578–74,139,390)x3 | 7q11.23(72,726,578–74,339,044)x3 | 7q11.23(72,726,578–74,139,390)x3 | 7q11.22q11.23(72,044,007–74,139,390)x3 | 7q11.23(72,283,565–74,134,911)x3 | 7q11.23(72,726,578–74,339,044)x3 | 7q11.23(72,726,578–74,119,570)x3 | 7q11.23(72,726,578–74,139,390)x3 | |
|
| 1.4 Mb | 1.4 Mb | 1.4 Mb | 1.6 Mb | 1.4 Mb | 2.1 Mb | 1.9 Mb | 1.6 Mb | 1.4 Mb | 1.4 Mb | 1.4–2.1 Mb |
|
|
| maternal | NA | paternal |
|
|
| NA | paternal |
| 5/8 |
|
| weight <3rd; height 3rd–10th; OFC 75th | weight >97th; height 90th–97th; OFC 50–75th | weight 10th; height 10th; OFC 25th | weight: 10th; height 97th; OFC >97th | Weight 50th–75th; height 25th–50th; OFC 75th–97th | Weight 50th– 75th; height 10th–25th | weight 50th-75th; height 25th–50th, OFC 50th | Weight:75th–97th; Height 25th–50th | weight: 75th; height 97th; OFC 75th | weight: 97th; height 50–75th | |
|
| |||||||||||
|
| relative | no | no | yes | relative | NA | no | no | no | NA | 3/8 |
|
| no | yes | no | no | no | NA | no | yes | no | NA | 2/8 |
|
| yes | yes | no | yes | no | NA | yes | yes | yes | NA | 6/8 |
|
| yes | no | no | yes | no | Yes | yes | yes | yes | yes | 7/10 |
|
| high nasal bridge | high nasal bridge | high nasal bridge with bulbous nose | high broad nasal bridge | normal | NA | bulbous nose | prominent, high nasal bridge | bulbous nose | NA | 5/8 high nasal bridge |
|
| additional crus of the antihelix, abnormally folded helix | horizontal crus of helix | asymmetric low set and posteriorly rotated | low-set posteriorly rotated ears with thickened earlobes | thickened helix | NA | no | no | thickened helix large ears | NA | 6/8 |
|
| no | yes | no | yes | no | prominent | yes | yes | yes | NA | 6/9 |
|
| yes | no | no | yes | yes | NA | no | NA | no | NA | 3/7 |
|
| yes | yes | yes | yes | yes, everted upper lip | No | no | no | yes | NA | 6/9 |
|
| NA | telecanthus, medial flaring of the eyebrow, exophoria | horizontal eyebrow, synophrys, short neck, pectus excavatum | prognathism, long chin with horizontal crease | micrognathia | NA | horizontal eyebrow; | overhanging columella | synophrys, hypertelorism, divergent strabismus | large incisors, short neck, low anterior and posterior hairline | |
|
| no | no | no | no | no | mild conductive (tubal stenosis) | no | no | no | no | 1/10 |
|
| no | mild ascending aortic dilatation | no | no | PDA, pulmonary valve dysplasia | No | PDA, mild tricuspid insufficiency | no | PDA(spontaneously resolved) | left ventricular hypertrabeculation, aortic insufficiency | 3/10 PDA; |
|
| no | yes bilateral | NA | yes bilateral | NA | no | NA | no | no | no | 2/7 |
|
| yes | no | yes | no | no | no | yes | no | no | yes | 4/10 |
|
| yes | no | yes | no | no | no | yes | no | no | yes | 4/10 |
|
| yes | yes | yes | no | no | yes | no | no | no | no | 4/10 |
|
| |||||||||||
|
| NA | Cerebral ultrasound: enlargement of periencephalic cerebral spaces | atrophy of EC with enlargement of the 3rd and lateral ventricles, thin corpus callosum | NA | NA | NA | normal | NA | normal | thin corpus callosum, arachnoid cyst | 2/5 thin corpus callosum |
|
| normal | normal | abnormal | NA | NA | NA | normal | normal | normal | normal | 1/7 abnormal |
|
| regular | regular | regular | NA | NA | irregular until 4 years | regular | regular | NA | NA | 1/6 irregular |
|
| periodic migraine episodes. hepatic steatosis | asthmatic bronchitis | Adenoidectomy; bronchospasm; | hypermetropia astigmatism | pharmacological therapy risperdone 0.25 mg (2 times per day) | periodic migraine episodes, pelvis dilatation | 2/10 migraine |
Legend: P: Patient; M: Male; F: Female; M: mean; SD: Standard Deviation; Mb: megabases; NA: not available; OFC: occipital frontal circumference; PDA: patent ductus arteriosus; MRI: Magnetic Resonance Imaging; EEG: electroencephalogram; EC: entorhinal cortex; mg: milligrams; ml: milliliters.
Cognitive, adaptive, language and visuo-motor assessment.
| Test | P1 | P2 | P3 | P4 | P6 | P7 | P8 | P9 | P10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 7.7 | 9.10 | 5.7 | 5.6 | 12.3 | 9.2 | 7.5 | 7.8 | 11.3 | M: 8.5; SD: 2.4 |
|
| 85 a | 47 b | 82 a | 81 a | 75 b | 81 a | 65 b | 62 a | 68 a | M: 71.77; SD: 12.39 |
|
| 71 c | 51 | 57 c | 54 c | 62 c | 85 c | 45 c | 38 c | 40 d | M: 55.88; SD: 15.13 |
|
| 55 c | 56 | 45 c | 51 c | 64 c | 71 c | 45 c | 40 c | 49 d | M: 52.88; SD: 9.84 |
|
| 82 c | 49 | 73 c | 58 c | 75 c | 107 c | 44 c | 42 c | 40 d | M: 63.33; SD: 22.61 |
|
| 87 c | 65 | 81 c | 71 c | 59 c | 82 c | 67 c | 54 c | 53 d | M: 68.78; SD: 12.46 |
|
| - | - | 54 c | 65 c | - | - | - | - | - | M: 59.5; SD: 7.78 |
|
| severely impaired | severely impaired | severely impaired | severely impaired | spared | slightly impaired | slightly impaired | severely impaired | severely impaired | 6/9 severely impaired |
|
| severely impaired | slightly impaired | severely impaired | severely impaired | spared | severely impaired | severely impaired | severely impaired | severely impaired | 7/9 severely impaired |
|
| severely impaired | slightly impaired | severely impaired | severely impaired | severely impaired | severely impaired | severely impaired | severely impaired | severely impaired | 8/9 severely impaired |
|
| 73 | 74 | 57 | 111 | 58 | 92 | 89 | 63 | 60 | M: 75.22; SD: 18.59 |
All scores are expressed in standard scores (Mean = 100; standard deviation: 15). Legend—P: patient; a: Leiter 3; b: WISC IV; c: VABS II; d: ABAS II; M: Mean; SD: standard deviation.
Autism symptoms, behavioral and psychopathological assessment.
| Test/Participants | P1 | P2 | P3 | P4 | P6 | P7 | P8 | P9 | P10 |
|---|---|---|---|---|---|---|---|---|---|
|
| 22 | NA | 22.5 | 36.5 * | 25.5 | 17 | 20.5 | 26 | NA |
|
| Not clinical | NA | Non clinical | Social Awareness | Social Awareness | Social Awareness | Social Awareness | Social Awareness | NA |
|
| Not clinical | NA | Not clinical | Attention Problem | Withdrawn/Depressed; Social Problems; Internalizing, Externalizing and Total Problems | Not clinical | Anxious/Depressed; Withdrawn/Depressed; Somatic Complaints; Social Problems; Thought Problems; Rule-Breaking Behavior; Aggressive Behavior; Internalizing, Externalizing and Total Problems | Anxious/Depressed; Withdrawn/Depressed; Social Problems; Thought Problems; Aggressive Behavior; Internalizing, Externalizing and Total Problems | Anxious/Depressed; withdrawn/Depressed; |
|
| Not clinical | Cognitive problems/inattention; Anxious–shy; Social problems; Psychosomatic; DSM–IV inattentive; DSM–IV total | Not clinical | Not clinical | Cognitive problems/inattention; Anxious–shy; Perfectionism; Social problems; ADHD index; CGI restless–impulsive; CGI emotional lability; CGI total; DSM–IV inattentive; DSM–IV total | Perfectionism | Oppositional; Cognitive problems/inattention; Hyperactivity; Anxious–shy; Perfectionism; Social problems; Psychosomatic; ADHD index; CGI restless–impulsive; CGI emotional lability; CGI total; DSM–IV inattentive; DSM–IV hyperactive–impulsive; DSM–IV total | Oppositional; Cognitive Problems/inattention; Hyperactivity; Anxious–shy; Perfectionism; Social problems; Psychosomatic; ADHD index; CGI restless–impulsive; CGI emotional lability; CGI total; DSM–IV inattentive; DSM–IV hyperactive–impulsive; DSM–IV total | NA |
|
| Variable functioning (60) | NA | NA | NA | Moderate degree of interference in functioning (50) | Moderate degree of interference in functioning (50) | Moderate degree of interference in functioning in most social areas (47) | NA | Major impairment of functioning in several areas (40) |
|
| Anxiety Disorder NOS (criteria not reached for Separation Anxiety Disorder and Social Phobia) | Anxiety Disorder NOS (criteria not reached for Generalized Anxiety Disorder) | Anxiety Disorder NOS (criteria not reached for Social Phobia) | Disruptive Behavior Disorder NOS | Disruptive Behavior Disorder NOS; Dysthymic Disorder | Generalized Anxiety Disorder (criteria not reached for Social Phobia) | Generalized Anxiety Disorder | Generalized Anxiety Disorder (criteria not reached for Social Phobia) | Generalized Anxiety Disorder (criteria not reached for Separation Anxiety Disorder and Social Phobia) |
|
| Specific phobia (birds); | Stuttering; | Selective Mutism Inhibition | Emotional dysregulation; hyperfagia; sleep talking; autistic features; alternate inhibition and social disinhibition (hugging non familiar people) | History of inhibition (actually social disinhibition); problem in motor regulation; repetitive behaviors; anxiety | Insistence on sameness; enuresis; emotional dysregulation; specific phobias; aggressive behaviors; social disinhibition (inappropriate sexual behavior; showing genitals); enuresis | Social disinhibition (hugging non-familiar people); emotional dysregulation; aggressive behaviors. | Behavioral oddities; Insistence on sameness; compulsive behaviors; imaginary friend |
Only scores of SRS, CBCL, CPRS-R, ranging in borderline/clinical results are reported. C-GAS scores in parentheses ( ). Legend: P: Patient; *: above cut-off for autism; NA: not available; CARS2: Childhood Autism Rating Scale, Second Edition; SRS: Social Responsiveness Scale; CBCL: Child Behavior Checklist; CPR-S: Conners Rating Scales—Revised; C-GAS: Children’s Global Assessment Scale; NOS: not otherwise specified; NA: not available; ADHD: Attention Deficit Hyperactivity Disorder; CGI: Conners’ Global Index; DSM-IV: Diagnostic and statistical manual fourth edition.
Presence/absence of anxiety/phobias, aggressive behaviors, separation anxiety/social inhibition, and repetitive behaviors/movements, disinhibition.
| P1 | P2 | P3 | P4 | P6 | P7 | P8 | P9 | P10 | T | |
|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety/Specific Phobias | + | - | - | - | + | + | + | + | + | 6/9 |
| Separation Anxiety/Social Inhibition | + | + | + | + | + | + | + | + | + | 9/9 |
| Aggressive Behaviors | - | - | - | + | + | - | + | + | - | 4/9 |
| Repetitive Behaviors/Movements | + | + | - | - | - | - | - | + | + | 4/9 |
| Social Disinhibition | - | - | - | + | + | - | + | + | - | 4/9 |
Legend: P: patient; +: presence of behavior; -: absence of behavior; T: Total.
Figure 1(a) Graphical representation of SNP-array result for patient 7. A microduplication is detected on the long arm of a chromosome 7, at 7q11.23, 1.9 Mb in size. (b) Enlargement of 7q11.23 genomic region. Gray background shadow highlights the OMIM genes normally included within the recurrent breakpoints reported for the microduplication syndrome. Blue lines represent the microduplications detected in our 10 patients.
Figure 2Photographs of patients with a 7q11.23 microduplication (P2, P4, P7, P9). Note macrocephaly, prominent forehead in some patients, elongated palpebral fissures, deep set eyes, palpebral ptosis, high prominent nasal bridge with bulbous nasal tip, short philtrum and thin vermillion of the lips.